Trends in Pharmacological Sciences
ReviewChirality in bioactive agents and its pitfalls
References (30)
- et al.
Annu. Rep. Med. Chem.
(1982) Eur. J. Clin. Pharmacol.
(1984)- et al.
Dtsch. Med. Wochenschr.
(1985) - et al.
- et al.
Science
(1983) - et al.
Ann. Appl. Biol.
(1952)
Naunyn-Schmied. Arch. Pharmacol.
Clin. Pharmacol. Ther.
Anesthesiology
Cited by (107)
A pre-trained multi-representation fusion network for molecular property prediction
2024, Information FusionGraphene oxide-doped chiral dextro-hydrogel promotes peripheral nerve repair through M2 polarization of macrophages
2024, Colloids and Surfaces B: BiointerfacesCopper-Catalyzed C−S Coupling of Quaternary Ammonium Salts and Dialkylcarbamodithioic Acid Salts
2020, Asian Journal of Organic ChemistryChiral pharmaceuticals: A review on their environmental occurrence and fate processes
2017, Water ResearchCitation Excerpt :However, most studies on ecotoxicity of pharmaceuticals overlooked chiral selectivity in toxicity by assuming that enantiomers exhibit identical biological activity. Several studies between 1960s and early 1990s showed that distomers often had low affinity for the primary drug target but could be a eutomer at a different receptor (Ariëns, 1986, 1984). Hence, Ariëns (1986) argued that distomers might be ‘harmful pollutants’ that could be injurious to the patient or environment.
A high throughput approach to purifying chiral molecules using 3μm analytical chiral stationary phases via supercritical fluid chromatography
2011, Journal of Chromatography ACitation Excerpt :Given the complex nature of biological targets, medicinal chemists are increasingly synthesizing compounds that have at least one chiral center [1,2]. FDA regulations state that compounds need to be tested in their enantiomerically pure state as the individual enantiomers may have vastly different pharmacological and toxicity profiles [3,4]. While creating an asymmetric synthesis route is desirable, it is often time consuming and expensive.